PDLIM7 and nasopharyngeal carcinoma: In addition to serving as a prognostic biomarker, our results suggest development of anti-LMP1 drugs could be a novel therapeutic strategy for NPC, NHL, and certain HD patients (i.e., depending on the patient's age and geographical location).